



**BRITISH
PHARMACOLOGICAL
SOCIETY**

Today's science, tomorrow's medicines



Annual Review
& Summarized Accounts
2012

Contents

- 3 President and Chief Executive's review
- 6 Objectives and Achievements
- 16 Membership
- 17 Meetings
- 20 Prizes and awards
- 23 Education and training
- 29 Industry update
- 30 Young Pharmacologists
- 31 External affairs
- 35 Publications
- 36 Structure, governance and management
- 38 Council
- 40 Executive Committee
- 42 BPS staff
- 44 Financial review
- 54 2013 objectives

Our mission

The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including the laboratory, clinical, and toxicological aspects.

BPS exists to promote and advance pharmacology (including, without limit, clinical pharmacology) and to be the leading Society for the presentation, promotion, and discussion of all matters relating to both pharmacology and clinical pharmacology and therapeutics (CPT). Specifically, the Society is concerned with the discovery, mechanism of action, use, and safety of drugs in humans and animals, in order to contribute to education and the understanding and relief of suffering.

The Society is a registered Charity. The Society's governing document is its Memorandum, Articles of Association, and Rules. In 1994 the Society became a Company Limited by Guarantee.

Registered charity name:
British Pharmacological Society

Charity registration number:
1030623

Company registration number:
2877400

Principal & registered office:
16 Angel Gate
326 City Road
London
EC1V 2PT

t: +44 (0) 20 7239 0171
f: +44 (0) 20 7417 0114

e: info@bps.ac.uk
w: www.bps.ac.uk

President and Chief Executive's review



BPS President *Phil Routledge*

2012 was an important year in the growth and development of BPS, with significant investment across our publications, meetings, education and communications activities yielding substantial contributions to the health and wealth of the United Kingdom, many of which are covered in detail throughout this Annual Review.

Perhaps the most significant event of the year was the Society's first Strategy Retreat, which brought together Trustees, members,



BPS Chief Executive *Jonathan Brünn*

journal editors and staff to plan for the next five years. The retreat identified outcomes and objectives, which are already helping to steer the Society through its decision-making processes with greater clarity of purpose. You can read more about the retreat online (bit.ly/ZMivfD) and appreciate how these initiatives have driven our 2013 objectives on P54 of this Review.

In the last year, as a direct outcome of the Strategy Retreat, we collaborated with

organizations from across the life sciences sector on matters of science policy, ethics and standards. BPS is becoming increasingly adept at promoting our discipline, while understanding that we are 'stronger together' with our partners.

Our members remain the lifeblood of the organization. Overall our membership grew again by about 7% to a figure in excess of 3,300. Growth was most obvious among our members at both ends of the career spectrum: initiatives to reinvigorate our Fellowships and Honorary Fellowships resulted in growth of 96% and 19% respectively over the course of the year, and we built our undergraduate and postgraduate categories by a combined 17% in the same period. It is reassuring that, at a time of challenge for pharmacology as an independent discipline in our academic institutions, we have been able to communicate its relevance to a growing number of young people.

Initiatives to engage better with new and existing membership groups, a key objective of the 2012 Strategy Retreat, prompted us to recruit two new members of staff in this area: Katharine Richardson joined as Head

of Communications and Membership, a role designed to give BPS increased strategic direction in the recruitment and retention of members; and Rebecca Tibbs was recruited as Education and Outreach Officer, raising our capacity to deliver high-quality academic and careers services to scientists and the public.

We are pleased the Society remains on a firm financial footing, with continued outperformance from our journals adding to the guaranteed income we receive as part of our publishing contract with Wiley-Blackwell. The income provided by our journals is critical to the ongoing health and effectiveness of the Society, and we are particularly grateful to all our editors, senior editors and our two Editors-in-Chief for their hard work in the pursuit of high-quality academic literature. Unfortunately, the Impact Factor of both journals dropped slightly in 2012, and we are committed to responding to this issue, and to continuing to advance the journals at a time of considerable upheaval in academic publishing.

Such commitment was behind our decisions, taken in 2012 but effective from 2013, to transfer the *British Journal of*

Pharmacology (BJP) and *British Journal of Clinical Pharmacology (BJP)* online, to give our editors and readers greater flexibility and provide opportunities for additional, valuable content in our journals. Additionally, we agreed to publish the Society's first wholly open access journal, *Pharmacology Research & Perspectives*, in tandem with two partners: the American Society for Pharmacology & Experimental Therapeutics (ASPET) and Wiley-Blackwell. There will be significant activity in this area from 2013 onwards.

As many who attended the BPS 2012 Winter Meeting will testify, our annual congress continues to go from strength to strength. The meeting, which was fully booked for the second year running and received excellent feedback, is testimony to the winning combination of scientific excellence and organizational nous. We are grateful to both Vice President–Meetings Professor David Webb and Head of Meetings Karen Schlaegel for putting together this terrifically successful event. We will build on this success with a larger capacity space at our venue in 2013 to accommodate more delegates and exhibitors at our annual congress,

now known as *Pharmacology 2013*.

In total, the Meetings team delivered 22 days of well-attended events, while distributing in excess of £30k in bursaries. Interestingly, non-BPS members made up 54% of meeting attendees, indicating that the Society is providing a balanced service: offering real value and opportunity for the sector as a whole, in addition to recognizing and delivering the scientific needs of its membership.

Our Education team, under the careful stewardship of Vice President–Academic Development Professor Nick Goulding and Head of Education Jess Strangward, were busy too, delivering in total: five workshops, two joint *in vivo* meetings, nine careers events, eight outreach events and one teacher event. *In vivo* work continued to be an understandable preoccupation for the Society, which funded 51 days of graduate *in vivo* training and distributed £100k through the Integrative Pharmacology Fund.

In addition, a close collaboration of our Education and Training Committee and the Clinical Pharmacology Section resulted in high profile achievements in the pursuit of

safer prescribing. In tandem with our partners the Medical Schools Council (MSC), we piloted the Prescribing Skills Assessment to 1,200 students in eight medical schools. Substantial grants from the Department of Health and NHS Education for Scotland for this and the Society's *Prescribe* e-learning project not only demonstrate that there is significant appetite for resources in this area, but also provide the Society with a valuable opportunity to enhance patient safety in the UK through education in and assessment of clinical pharmacology and prescribing.

Another major project [GuidetoPharmacology.org](#), an online portal containing cross-referenced, curated and peer-reviewed data on drug targets and the prescription medicines and experimental drugs that act on them, also received substantial funding. The Wellcome Trust granted the project over £500k, contributing to the long-term viability of this important project and again demonstrating that BPS is at the forefront of the provision of resources to drug discovery and development teams worldwide.

In January, our Chief Executive Kate Baillie announced that she would be moving on to pastures new as Chief Executive of the

Biochemical Society. Kate had done a fantastic job over the previous 4½ years in modernising BPS, streamlining the office and building strong links with other organizations in the sector and across the world, and we are hugely grateful for her contribution.

Sadly, we also said farewell to some of the Society's committed volunteers, Committee Chairs and Honorary Officers in 2012. Professor Emma Baker and Drs Mark Christie and Ann Hayes stepped down as Trustees of BPS, while Professor Nick Goulding demitted from his role as Vice President–Academic Development. Professor Jane Mitchell completed her term as Chair of the Young Pharmacologists Committee and Dr Martin Todd stood down as Chair of the Industry Committee.

The Society relies on support from its members, particularly those who work on a voluntary basis as committee members, Honorary Officers, journal editors and reviewers, in order to deliver the tremendous results we have outlined above. We would like to extend our thanks to all these individuals, including the staff team at The Schild Plot, for making 2012 another excellent year for BPS.



Jonathan Brüün
BPS Chief Executive



Phil Routledge
BPS President

Objectives

1. To maintain and develop services for members:

- Conducting a widely-based membership survey in order to analyse and understand the needs of different member cohorts, and provide targeted benefits for each group
- Enhancing online services for our journals through support for *The Guide to Pharmacology*, exploration of open access journals and a phased move to online only publication of *BJP* and *BJCP*
- Further improving links between our journals and our meetings
- Raising the profile, visibility and ultimately the Impact Factor of our journals
- Developing the content and influence of our newsletter, *Pharmacology Matters*

Achievements

- BPS delivered a membership survey on our meetings and events that found exceptionally high levels of satisfaction. This will inform the work of BPS Meetings Committee and the development of a larger scale membership survey on all aspects of BPS activity in 2013.
- Phased activity throughout 2012 ensured readiness for *BJP* and *BJCP* moving online only as of 1 January 2013. BPS online journals will offer authors and readers greater flexibility and new features.

BPS, ASPET and publisher Wiley-Blackwell reached agreement on the publication of a new, jointly-owned, open access journal, *Pharmacology Research & Perspectives*.

BPS continues to actively support GuidetoPharmacology.org, as a free to access “one-stop shop” source of information on drug targets and the prescription medicines and experimental drugs that act on them. In 2012, the Wellcome Trust awarded the project a generous grant of £551,750 to facilitate the extension of this key resource.
- BPS strengthened links between BPS journals and meetings through *BJCP* and *BJP* symposia and Meet the Editor sessions during the BPS Winter Meeting. BPS journals also regularly receive review content from BPS meetings.
- BPS journals are well-received when BPS exhibits at international meetings, which in 2012 included the Society for Neuroscience (>30,000 delegates) and Experimental Biology (>14,000 delegates). Public relations activity raised the profile of our journals, resulting in significant international media coverage.
- BPS used targeted issues of *Pharmacology Matters* to raise the profile of BPS and highlight the value of UK pharmacology by leveraging major milestones: a drug development issue in April ahead of the Olympic Games; our July issue was included in every delegate bag at the 2012 Federation of European Pharmacological Societies (EPHAR); and December’s issue echoed the science communication focus of our Winter Meeting. The July issue was our most widely read with 7,780 clicks from online readers in 38 different countries.

Objectives

2. To ensure the delivery of training and education in pharmacology:

- Provision of high quality scientific meetings, with attractive topic selections
- Continued participation in the meetings of relevant external groups and by arrangement of joint meetings, maximising benefits to members and stakeholders
- Mapping clinical, industrial and academic skills needs, and delivering effective and leading edge educational courses for clinical and basic scientists including provision for CPD
- Continued delivery and development of the Diploma in Advanced Pharmacology and its component workshops
- Conducting a survey of the teaching of pharmacology at undergraduate and postgraduate level

Achievements

- BPS delivered three Focused Meetings and our Annual Winter Meeting in 2012. These attracted ~1,200 delegates in total, receiving excellent feedback from delegates, speakers and exhibitors. Sessions attracted both members and non-members (accounting for 54% of attendees).
- BPS participated in joint meetings in collaboration with other leading life sciences organisations in the UK and internationally: Society of Biology, the Physiological Society, the Royal College of Physicians of Ireland, the Federation of European Pharmacological Societies (EPHAR), the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) and Understanding Animal Research to name but a few.
- BPS led a cross-learned society initiative to map core skills gaps in drug discovery, and is committed to working with the group beyond 2012 to deliver our objectives. BPS Diploma Workshops and Winter Meeting received CPD accreditation from Society of Biology, while the Speciality Registrar (SiR) session at the Winter Meeting secured CPD accreditation from the Royal College of Physicians. BPS funded 51 days of graduate *in vivo* training and distributed £100k through the Integrative Pharmacology Fund.
- Our Diploma in Advanced Pharmacology continues to support excellence in pharmacology: Six BPS members graduated from the course during 2012 and four out of our five 2012 Diploma Workshops were sold out.
- BPS Committee of Heads and Professors of Pharmacology and Therapeutics agreed that this one-off survey would not be taken forward. Other mechanisms for fulfilling the delivery of training and education in pharmacology will be explored.

Objectives

3. To promote pharmacology as a scientific discipline:

- Building our portfolio of outreach initiatives through enhanced contributions to careers fairs, teachers' conferences, science festivals and other outreach events
- Developing our online networking communities
- Using our websites, the main bps.ac.uk and the specialised PharmacologyNow.org, to promote careers in, and public understanding of pharmacology
- Ensuring that the importance of pharmacology and the views of pharmacologists are fully represented in government and other policy consultations

Achievements

- BPS outreach initiatives included contributions to nine careers fairs plus other events and science festivals. Highlights included the launch of teachers' outreach grants, two (sold out) lectures at the Science Museum's Dana Centre and collaborations with university pharmacology societies.
- Our online networking communities continued to grow during 2012, achieving >3,000 followers across all communities by the end of the year. BPS further developed our [@britpharmsoc](#) and [facebook.com/britpharmsoc](#) pages, as well as the launch of [@pharmacologynow](#).
- [bps.ac.uk](#) continued to be a key resource for careers information and educational resources: these pages appeared in the top 20 of those accessed by visitors, and the site as a whole finished the year with more than 55k unique hits. A soft launch of [PharmacologyNow.org](#) in 2012 provided a hub for BPS educational and outreach activities, with a full launch planned for 2013.
- BPS was actively involved in the Science Parliamentary Links Day on 26 June and made a keynote presentation on pharmacology and policy at a dedicated parliamentary reception on science in December. BPS responses to 13 key consultations were submitted during 2012 in order to represent the views and expertise of our members.

Objectives

4. To promote clinical pharmacology as a clinical discipline

- Developing *Prescribe*, a web-based training tool for medical students and other health professionals with prescribing responsibilities
- Working with the Department of Health's e-Learning for Health Initiative to deliver a Prescribing Simulator
- Working with the MSC and other stakeholders to develop a national Prescribing Skills Assessment for all final year medical students
- Encouraging training and appointment within universities and the NHS of clinical pharmacologists to contribute to the delivery of healthcare, research, education in therapeutics and prescribing, and medicines policy at local, regional and national level

Achievements

- BPS continued to develop *Prescribe* in 2012, delivering a range of new e-learning resources. An award of £102k by the Department of Health will enable us to provide 20 additional teaching sessions on prescribing skills.
- The Prescribing Simulator was expanded during 2012, with the support of trained Prescribing Skills Assessment item writers. In total 200 new items are currently in peer review and will be available via the Simulator in 2013.
- The national Prescribing Skills Assessment pilot was delivered online by BPS and MSC to eight medical schools, encompassing ~1,200 students. Detailed psychometric analysis of the 2012 results provided recommendations for improving reliability in future phases.
- *Clinical Pharmacology in Health Care, Teaching & Research* is a joint publication between the World Health Organization (WHO), International Union of Basic and Clinical Pharmacology (IUPHAR) and the Council for International Organizations of Medical Sciences (CIOMS). BPS funded the printing of this report and highlighted relevant findings to our members, Learned Societies and policy makers.
- BPS is developing new clinical careers leaflets and gathering case studies to illustrate the impact of clinical pharmacologists.

Objectives

5. To develop collaborative activities with other societies in order to promote pharmacology and clinical pharmacology:

- Actively engaging with Society of Biology in projects, including accreditation, education, outreach and science policy
- Continuing the work of the Industry Committee (with Society of Biology, Royal Society of Chemistry and Academy of Medical Sciences) to promote the provision and understanding of pharmacology and clinical pharmacology in the pharmaceutical industry
- Developing and extending links with sister societies nationally and internationally

Achievements

- All BPS careers events in 2012 were delivered in partnership with Society of Biology (and additional bioscience society partners). BPS joined with Society of Biology during SCORE (Science COmmunity Representing Education) committee meetings, and in reaching out to Government and other key stakeholders. BPS provided two assessors to advise on the accreditation of *in vivo* courses, as well as developing new careers posters for 14-16 year olds and a new CPD event for teachers.
- BPS co-organized a meeting of over 20 Learned Societies in February 2012 to discuss skills gaps and provision. BPS is a founding member of the DDPG (Drug Discovery Pathway Group) with Society of Biology, Academy of Medical Sciences, Royal Society of Chemistry and Biochemical Society. The group aims to discuss and make recommendations for improvement of sector skills, CPD and academia-industry permeability.
- Through joint symposia and meetings, educational and outreach events and science policy initiatives, BPS collaborated with International, European, American, Australian, Chinese, and Austrian pharmacological societies. We also met with the leaders of six separate European Pharmacological Societies at the 2012 EPHAR Congress. In addition, BPS continued to work with valued partners including the Physiological Society, British Neuroscience Association, Royal Pharmaceutical Society and others on cross-sector activities.

Membership

The total BPS membership on 31 December 2012 was 3,301, representing a rise of 7% in a year. Undergraduate Membership notably rose 21% with students continuing to take advantage of this free category of membership.

The Membership and Awards Committee encouraged existing Associate Members, who they felt qualified for Full Membership, to upgrade. 25% of those contacted have already done so. Associate Membership is now limited to five years and those completing this term will either upgrade to Full Membership or move to Affiliate Membership.

121 Members and 607 associate members (including undergraduate and postgraduate students) were also elected during the year.

During 2012, the Membership and Awards Committee encouraged existing Full Members, who they felt had demonstrated distinction and peer recognition in pharmacology, to apply for Fellowship. BPS was therefore delighted to welcome 90 new Fellows in 2012, increasing the total Fellowship to 186, alongside the election of the following new Honorary Fellows:

Professor John Coote; Professor Dame Sally Davies; Professor Sir Gordon Duff; Professor Roderick Flower; Professor Brian Kobilka; Professor Robert Lefkowitz; Professor Gordon McInnes; Professor Daniel McQueen; Professor Roger Pertwee; Professor Ursula Ravens; Professor Iain Robinson; Professor Dame Nancy Rothwell; Dr Robertson Towart and Professor Arthur Weston.


In 2012 the Clinical Pharmacology Section Committee produced a membership leaflet to encourage membership of the Society amongst those with an interest in clinical pharmacology.



The Clinical Pharmacology Section developed their own membership leaflet during 2012

There are 655 members of the Clinical Pharmacology Section, of whom 116 are undergraduate or postgraduate members.

The Society was sad to report the deaths of 16 members.



7% growth in membership with increases across most categories in 2012

Meetings

Key highlights and delegate feedback from our programme of meetings in 2012:

The Biomedical Basis of Elite Performance, London

19–21 March 2012, jointly organized with The Physiological Society

- 492 registrations, which included 49 speakers
- 19 exhibitors

“It was the best value for money conference I have attended”

4th Focused Meeting on Cell Signalling, Leicester

23–24 April 2012, organized by Professor John Challiss, Professor Andrew Tobin and Dr Gary Willars, University of Leicester

- 195 registrations, which included 20 speakers
- Five exhibitors

“Quality of speakers was very good”

Rational and Safe Prescribing: the way forward, Dublin

11 May 2012, jointly organized with the Royal College of Physicians Ireland; scientific lead: Professor David Williams, Royal College of Surgeons, Ireland

- 81 registrations, which included 10 speakers

“Excellent programme of speakers really enjoyed the day”

“Very efficient, well organized, wonderful meeting”

Focused Meeting on Neuropeptides, London

7–9 June 2012, in association with the European Neuropeptide Club and American Summer Neuropeptide Conference, organized by Professors Sue Brain and Helen Cox, King’s College London

- 104 registrations, which included 25 speakers
- Five exhibitors

“Everything was very well run”

“The organizers did a fantastic job!”

Winter Meeting 2012, London

18–20 December 2012, held at the Queen Elizabeth II Conference Centre for the fourth time.

- 805 registrations, which included 68 speakers
- 19 exhibitors and three sponsors

The conference was comprised of nine symposia, four oral communication sessions and four poster sessions. As in previous years, Undergraduate Bursary Prize Winners were invited to present at the Meeting.

The Society was pleased to welcome the British Society for Cardiovascular Research, the British Toxicology Society and the Safety Pharmacology Society as symposia organizers in 2012.

The SiR training session, *CPT Curriculum Training: Adverse Drug Reactions & Pharmacoepidemiology*, took place within

Meetings (continued)

the Winter Meeting programme. The session covered: Adverse drug reactions – classification & mechanism, Adverse drug reactions – identification & management, and Pharmacoepidemiology. The training was followed by an assessment sat by 16 StRs.

The Annual Dinner and Prize Giving again took place at the award-winning Church House Conference Centre. Guests enjoyed a prize reception in the Hoare Memorial Hall, followed by dinner in the Grade II listed Assembly Hall.

Podcasts and vodcasts are available via the BPS website.

“Really important meeting in the pharmacology calendar – UK pharmacology footprint is world class”

“My first time at BPS and I found it very professional and enjoyable”



Professor Rod Flower discusses his outreach activities in Pharmacology Corner at the Winter Meeting 2012

Prize lectures

- **AstraZeneca Women in Pharmacology lecture:** “Nitric oxide, Prostacyclin and ET-1; lessons in life from the vessel wall” by Professor Jane Mitchell, Imperial College London
- **Gaddum Prize lecture:** “Inhibitory Cys-loop Neurotransmitter Receptors” by Professor Trevor Smart, University College London
- **Gary Price Memorial Lecture:** “Gary, GABA and 5-HT: Eliciting information about Cys-loop receptors from bacteria” by Professor Sarah Lummis, University of Cambridge
- **JR Vane lecture:** “Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery” by Professor Edith Sim, Kingston University
- **Lilly lecture:** “Harms from medicines: inevitable, in error, or intentional” by Professor Robin Ferner, University of Birmingham

- **Paton lecture:** "A history of the glucocorticoids - a stressful tale" by Professor Nick Goulding, Barts and the London School of Medicine & Dentistry
- **MSD lecture:** "Gene doping: of marathon mice and men" by Dr David Bishop-Bailey, Barts and the London School of Medicine & Dentistry




Professor Edith Sim gave the 2012 JR Vane Medal prize lecture



Professor Nick Goulding gave the 2012 Paton prize lecture

Clinical Pharmacology Section Regional Funding

- A meeting of the Caledonian Society of Clinical Pharmacology
2 November, Dundee
- Support for the All Wales Medicines Strategy Group meeting
24 May, Cardiff



Clinical posters presented at the Winter Meeting 2012

Prizes and awards

Congratulations to our 2012 winners:

AstraZeneca Prize for Women in Pharmacology

- Professor Jane Mitchell, Imperial College London

BPS Bill Bowman Travelling Lectureship

- Dr Emma Robinson, University of Bristol & Dr Kathryn Yuill, University of Plymouth

BPS JR Vane Medal

- Professor Edith Sim, Kingston University

BPS Teaching Prize: "The Rang Prize"

- Dr David Lewis, University of Leeds & Dr Kyle Gibson, University of Edinburgh

Drug Discovery of the Year

- The vismodegib discovery team Collected by Rick Graham, Clinical Pharmacologist and acting Global Development Leader for vismodegib at Genentech

Gaddum Memorial Award

- Professor Trevor Smart, University College London

GlaxoSmithKline Prize for Research in Clinical Pharmacology

- Professor Amrita Ahluwalia, William Harvey Research Institute

Novartis Prize

- Dr Dean Naisbitt, University of Liverpool

Sir James Black Award for Contributions to Drug Discovery

- Dr Simon Campbell, Formerly Pfizer

BJCP Young Investigator Prize

- Dr Ying J. Cao, John Hopkins University

BPS AJ Clark Studentship

- Jenna Turner, University of Nottingham

BPS and ASCEPT Outstanding Young Investigator Award

- Dr Celine Valant, Monash University

BPS Post-doctoral Support

- Dr Eerik Aunin, King's College London

BPS Vacation Studentships

- Catherine Crook, King's College London
- Stephanie Smith, University of Cambridge

- Janki Gore, University Of Dundee
- George Lester, University of Southampton
- Danyele Carr, University of Glasgow
- Cai Read, University of Cambridge
- Sarah Dyball, Brighton and Sussex Medical School
- Marc Moore, Royal Holloway, University of London
- Yuan Chao Xue, St. George's, University of London

GlaxoSmithKline Award for Young Investigator

- Georgina Apostoli, Imperial College London

Schachter Award

- Luan Koay, Lancaster University & Ayah Siddiqi, De Montfort University

Science, Engineering and Technology (SET) Award for Best Pharmacology Student

- Amy Monaghan, University of Edinburgh

BPS Poster Prize

- Lineu Baldissera, State University of Campinas

GlaxoSmithKline Prize for CPS Oral Communications

- Christopher Floyd, King's College London

Pfizer CPS Poster Prize

- Lalarukh Haris Shaikh, University of Cambridge

CPS Undergraduate Prize Winners

- Therapon Chrisostomou, University of Birmingham
- Anna Forbes, University of Birmingham
- Richard Bagshaw, University of Birmingham
- Murray Philip Connolly, University College Cork
- Catherine Williamson, University of Glasgow
- Waqass Farid, Hull York Medical School
- Matthew Emile Li Kam Wa, Imperial College London
- Darren Anderson, King's College London
- Omonivie Okaisabor, King's College London
- Laura Beswick, King's College London
- Melanie Davis-Hall, University of Nottingham

- Alexander Brooman-Gannon, Peninsula College of Medicine and Dentistry
- Jonah Fox, Peninsula College of Medicine and Dentistry
- Mary Flanagan, Royal College of Surgeons in Ireland
- Peter De La Harpe Golden, Royal College of Surgeons in Ireland
- Richard Siau, St. George's, University of London
- Jagdeva Mehet, St. George's, University of London
- Emily Zinser, University College London
- Thomas James, University of Warwick
- Joanne Kelly, University of Edinburgh
- Kristina Lee, University of Edinburgh
- Jennifer Sinclair, University of Aberdeen
- Archana Depala, Barts and the London
- William Hunt, Bristol University
- Thomas Hathaway, Cardiff University
- Anna Kirov, University of Liverpool
- Holly Brown, University of Liverpool
- Kamlesh Sreekissoon, Newcastle University
- Kate Wannop, University of Oxford

- David Holmes, Queen's University Belfast
- Claire Calderwood, University of Southampton
- Sarah Leir, University of Southampton
- Michelle Smith, University of East Anglia

Prize for the Best National Young Investigators poster in Clinical Pharmacology

1. Claire Calderwood, University of Southampton
2. Jennifer Sinclair, University of Aberdeen
3. Michelle Smith, University of East Anglia

With thanks

We would not be able to offer this variety of prizes and awards without support from our sponsors:



Prizes and awards gallery



Professor Amrita Ahluwalia (right) receives the GSK Clinical Prize for Research in Pharmacology



Melanie Davis-Hall, one of our 33 Clinical Pharmacology Section Undergraduate prize winners



Professor Trevor Smart (left) receives the Gaddum Memorial Award

Education and training

2012 saw the education and training activities of the Society continue to grow. In order to support the Society's new strategic aim to "explain the importance of pharmacology in the modern world by extending BPS outreach activities" we recruited a new Education and Outreach Officer, Rebecca Tibbs. We also said farewell to Professor Nick Goulding who ended his term as Vice President–Academic Development at the end of 2012.

Diploma in Advanced Pharmacology

The Diploma continued to attract new applicants during 2012 and by the end of the year we had 28 registered candidates. BPS was delighted that six Diploma students graduated at the 2012 Winter Meeting: Ustav Bali, Inmaculada Bellido, Laurice Fretwell, Linda Kitching, Cheryl Parry and Iván Rodríguez.

Diploma workshops

Students undertaking the Diploma must complete six workshops however these intimate, specialized and highly interactive meetings are sought after by a range of delegates and

sell out on a regular basis. In 2012 we ran the following workshops:

- Statistics (11 April; Kings College London) 22 delegates
- Pharmacokinetics & Pharmacodynamics (25 May; Charles Darwin House, London) 25 delegates
- Safety Pharmacology (20 June; Covance, Harrogate) 15 delegates
- Neuroprotection (20 October; QMUL, London) 20 delegates
- Drug Discovery (17–18 December; Coin Street, London) 26 delegates



Dr Laurice Fretwell receives her Diploma in Advanced Pharmacology

PharmaCALogy

PharmaCALogy continued to play a vital role in the education of undergraduate pharmacologists in the UK as well as multiple audiences across the world. The Education and Training Committee agreed to commit funding to aid the replatforming of this valuable programme.

Research Excellence Framework Meeting

CHOPT (Committee of Heads and Professors of Pharmacology and Therapeutics) held a day long REF (Research Excellence Framework) meeting in April 2012. The meeting gave advice and offered support to members preparing for REF 2014 and acted as a forum to discuss how pharmacology research may be assessed in future. A report of the meeting was circulated widely and appreciated by many members in their REF preparations.

The future of the PhD

CHOPT contributed to a BPS-led consultation on ORPHEUS (Organization for PhD Education in Biomedicine and Health Sciences in the EUropean System). Professor

Education and training (continued)

Nick Goulding wanted to ensure that the UK viewpoint was taken in account in these broad European discussions around the future of the PhD. This led to a presentation at a specialist EP HAR Education Symposium. Due to the proactive work of BPS, this has now become a sector-wide issue involving Society of Biology and work will continue during 2013.

Prescribing Skills Assessment

The Prescribing Skills Assessment (PSA) is a joint project with the Medical Schools Council (MSC) to develop a reliable and valid assessment of prescribing skills for final year medical students that will allow them to demonstrate that they are safe and competent prescribers.

A pilot was delivered in eight Medical Schools to over 1,200 students to test the robustness of the system and to confirm medical schools' ability to deliver an online assessment. The feedback from both a technical and student perspective was very positive. Psychometric analysis of this small cohort led to the decision, with advice from the MSC - Assessment Alliance, to double the length of the PSA to two hours

and modify all questions to the 'best of five' format.

In February 2012 the PSA team held their first 'PSA Item Authors Peer Review Meeting', which generated over 800 questions. BPS extends its thanks to those members who volunteered their time and the Medical Schools who supported the PSA during 2012.

Prescribe

Prescribe aims to provide e-learning materials to help medical students (and students of other healthcare professions) to develop a firm grounding in the principles of basic and clinical pharmacology. There are approximately 1,500 registered users of *Prescribe* from UK medical schools. There are currently sixteen 25 minute e-learning sessions available.

In July 2012, BPS was awarded a £102k grant from the Department of Health's e-Learning for Health (eLH) to complete a further 25 modules. A host of members volunteered to write sessions by the end of 2012, led by Professor Simon Maxwell. These modules will be hosted at prescribe.ac.uk.

Prescribing Simulator

BPS is working with eLH to develop and populate the Prescribing Simulator. The Prescribing Simulator is an online training environment that provides the opportunity for those learning to prescribe to practise in a simulated online environment at any time or place.

Clinical Pharmacology in Healthcare, Teaching & Research Report

The Clinical Pharmacology Section supported the publication of *Clinical Pharmacology in Healthcare, Teaching & Research* in 2012. The report was produced by IUPHAR, CIOMS and WHO.



The report can be accessed at bit.ly/15xlgKL

Careers

Following a successful launch of our new *Careers in Pharmacology* and *How Do Drugs Work?* leaflets, we have distributed over 8,000 leaflets during Open Days, Careers and Outreach events in 2012.

Association for Science Education Annual Conference (6–7 January, University of Liverpool)

BPS co-organized a 'Biology in the Real World' symposium at this major science education event with other Society of Biology member organizations. The BPS talk was given by Dr Valerie Gladwell from the University of Essex entitled 'The 5 Rings of Success' as part of a wider programme themed around sport and the Olympics.

Careers Fairs

BPS travelled across the country to schools, universities and careers fairs to inform students about pharmacology, inspire students to consider a career in pharmacology and promote the supportive role of the Society. Together with our sister societies, we attended or sent materials to the following events:

- National Careers Guidance Show
- Three UCAS fairs
- NatureJobs Careers Expo
- The Engineering, Science & Technology Fair

In addition, members of the Clinical Pharmacology Section attended the following careers events on behalf of BPS, raising awareness of the specialty:

- Royal College of Physicians' Medical Open Day
- Cardiff University Careers Day organized by Cardiff University's Medicine & Pharmacology Society

Make a Difference Posters

Biological societies collaborated during 2012 to produce posters aimed at encouraging 14–16 year olds to 'Make a Difference' with a career in biology. These were sent to secondary schools and were accompanied by a new online portal, biology-careers.org, with further information about different careers related to studying biology. BPS was responsible for writing the 'Medicine' section.



Life Sciences Careers Conference (LSCC)

The LSCC is a careers fair for undergraduate studying biology. BPS sponsored this initiative, which entitled us to a stand at three 2012 events. We sent representatives to the following events:

- University of Birmingham - 14 November 2012
- Queen's University Belfast - 28 November 2012
- University of Leeds - 5 December 2012

Education and training (continued)

Promoting women's careers

AstraZeneca Prize for women in pharmacology

Professor Jane Mitchell presented 'Nitric oxide, prostacyclin and ET-1; lesson in life from the vessel wall' to a packed auditorium at the 2012 Winter Meeting.

Mentoring Scheme

The mentoring scheme has been in operation since 2005. The scheme provides individuals with a mentor so that they can confidentially discuss a wide range of issues that might influence their career progression. In 2012 we paired 12 mentors with mentees.

Career Crossroads to Career Development workshop

The Women in Pharmacology Committee organize annual skills training workshops which are free to BPS members. In 2012, we ran a career development workshop, *Career Crossroads to Career Development*. This workshop attracted 11 attendees and was considered "useful and inspiring" by delegates.

SCORE – Science COmmunity Representing Education

BPS is a contributing member to SCORE and for 2012 our Head of Education Jess Strangward was a committee member. In a year when the Government's eyes were focused keenly on all levels of education, it was SCORE that represented the scientific community directly to Government. This included a face to face meeting with Liz Truss MP about the potential changes to GCSEs.

Supporting *in vivo* training

Integrative Pharmacology Fund

In 2004, a consortium of three pharmaceutical companies (AstraZeneca, Pfizer and GlaxoSmithKline) established the £4million BPS Integrative Pharmacology Fund (IPF). In 2012 the fund continued to support high quality *in vivo* research and training in UK academic institutions in the following ways:

- Funding to cover the *in vivo* costs of 18 MRC PhD and 28 MRRes projects at the Universities of Bristol, Cambridge, Glasgow, Liverpool, Imperial College London and Queen Mary, University of London

- A new Strategic Skills Award scheme with the BBSRC and the MRC provided support for research training in advanced integrative mammalian biology
- An Undergraduate Bursary fund helped undergraduates gain *in vivo* skills. In its first call it has awarded £1.5k of funding
- A Masters Bursary fund awarded £5k to St George's, King's College London, Manchester University and Strathclyde for the next three years
- Pump Priming Initiative was designed to promote new research ideas that require the use of *in vivo* mammalian (non-human) animals. Grants will be up to £10k and must be used for consumables animals and/or essential new equipment or travel to a collaborating laboratory to learn novel techniques. Awards were made to Dr Michael Emerson and Dr James Dachtler

In vivo training fund

This fund supported *in vivo* training courses at six universities in 2012 (Bath, Bristol, Glasgow, King's College London, Leeds and Manchester). This funding was only possible with generous support from the Integrative

Pharmacology Fund, AstraZeneca, Eisai, Lilly, GlaxoSmithKline, Huntingdon Life Sciences, Novartis, Pfizer, and Takeda.

BPS/Physiological Society *in vivo* short courses

In 2012 the three annual short courses, offering *in vivo* training to those who cannot access it at their home institutions were held at King's College London, the University of Glasgow and Bristol University, attracting 28 students. In 2012 BPS secured additional funding from the Wellcome Trust, the MRC and BBSRC to support the continuation of these courses and to add two further courses at Strathclyde and the University of Glasgow.

In vivo policy work

Time for Change

Throughout 2012 the UK Parliament was working towards implementing the new EU Directive on animal research before it became law on 1 January 2013. In order to support the community BPS, the Physiological Society, Society of Biology and Understanding Animal Research jointly produced the 'Time for Change' meeting. This included a keynote speech from

Judy MacArthur Clarke, the Home Office Chief Inspector, informing the community of the upcoming legislation change. This was followed by industry and academic voices outlining how they were preparing their institutions for change and dedicated workshops, for topics such as 'openness in research'.

Joint NC3Rs, Physiological Society and BPS meeting on Pain Models

The NC3Rs, BPS and the Physiological Society hosted a joint symposium on 11 October 2012 to discuss opportunities for developing new and improved models of experimental pain, with reduced reliance on animal models. BPS is committed to ensuring our members are contributing to the work of the NC3Rs and our journal output is in line with the ARRIVE guidelines.

Animal Research gets political

BPS provided financial support to allow Understanding Animal Research to attend the Labour and Conservative Party Conferences to ensure that parliamentarians were aware of the issues around the new EU Directive. This was felt to provide balance and ensured the views of the research community were represented.

Outreach

Inside Shakespeare's Medicine Cabinet – Dana Centre London

Professor Rod Flower and a team of actors delighted audiences with a variety of scenes from Shakespeare that demonstrated how the Bard used medicines in his plots. This event sold out (over 120 participants).

Pharmacology Corner

The BPS Outreach Committee invited members to share their experience of doing pharmacology based outreach at the BPS Winter Meeting. BPS is committed to raising the profile of pharmacology through public engagement and this showcased the different ways it could be achieved from talks in schools to Science Festivals.

Cheltenham Science Festival

BPS continued its long standing collaboration with Cheltenham Science Festival as a partner in 2012:

The Science of Honey

Professor Clive Page, Professor Andrea Sella, Dr Mark Miodownik and Dan Basterfield covered everything from examining the

Education and training (continued)

structure of a beehive to the medicinal properties of honey. It was a sold out Friday night event that really got the crowd buzzing.

Parkinson's

Professor Peter Jenner's event explored new treatments for Parkinson's and how our understanding of it has changed over the years.

Dr Barry Marshall: A Human Guinea Pig

Dr Jeff Aronson delighted the crowd with tales of self-experimenters through the ages. He introduced Nobel Laureate Dr Barry Marshall and showed that pharmacologists are always the first to volunteer!

How do drugs work?

BPS explored more interactive territory by encouraging members of the public to tell us what medicines they were taking. Our clinical pharmacologists then explained how they worked.


PharmacologyNOW – Twitter and blog

Late 2012 saw the launch of the new BPS Outreach Twitter feed and a blog to showcase our outreach activities.

Higher education

Accreditation

Society of Biology continues to work with BPS and the Physiological Society to accredit *in vivo* courses. It is hoped that it will be possible to accredit Masters courses as this is where most *in vivo* work takes place. BPS members and staff have been appointed to key roles on accreditation planning committees and we continue to be consulted as accreditation moves into its next phase.



Inside Shakespeare's Medicine Cabinet demonstrated how the Bard used medicines in his plots

Industry update

The Industry Committee was officially established in 2011 (from a working group set up in 2010) and seeks to act as a steering and coordination group for all industry-related matters.

In February 2012, Dr Martin Todd retired as Chair of the Industry Committee. We are grateful to Dr Mark Christie who took over as interim Chair until the next election. Dr Ann Hayes was elected as Chair of the Industry Committee at the 2012 AGM. Industry activity in 2012 included:

Drug Discovery of the Year Award

The Industry Committee ran, and judged, the first annual Drug Discovery of the Year Award, which was won by the discovery team developing vismodegib for the treatment of advanced basal cell carcinoma (a type of skin cancer).

The award was created to celebrate the importance of pharmacology in the development of new medicines. The winning team was selected following nominations made to BPS by its members worldwide. Rick Graham, Clinical Pharmacologist and acting Global Development Leader for vismodegib

at Genentech, collected the award at the BPS Annual Dinner.

Collaboration with other Societies

In February 2012 the Committee organized, in conjunction with Society of Biology, a meeting of 22 Learned Societies to discuss skills provision for drug discovery. The work from this meeting is currently ongoing, focusing on three main areas: skills, permeability and continuing professional development. The Industry Committee work with Royal Society of Chemistry, Academy of Medical Sciences and Society of Biology has led to meetings with the life sciences advisor Sir John Bell and a series of *Research Fortnight* articles.

Consultations

The Industry Committee responded to the Commons Select Committee inquiry on 'bridging the "valley of death": improving the commercialisation of research' and to the recent EU 'consultation on plans for public-private partnership in life sciences research and innovation under Horizon 2020'.

Outreach to redundant pharmacologists

The Industry Committee offers complimentary membership to redundant pharmacologists. 62 people took up this offer and, in 2012, 11 converted to Full Membership.



Rick Graham (left) collected the Drug Discovery of the Year award at the BPS Annual Dinner

Young Pharmacologists

The Committee organized a number of activities during 2012:

Sponsored talks and events

Student members can request funding to organize a BPS sponsored talk or event at their university. 2012 Winter Meeting we sponsored talks and events in Bath, Cardiff, Dundee, Edinburgh, Glasgow, London, Oxford and Southampton.

Fundraising for IUPHAR 2014

Fundraising efforts continued during 2012 to provide bursaries for scientists from countries in Africa to attend WorldPharma 2014, which will take place in Cape Town, South Africa. Combined sales of I ♥ Pharmacology T-shirts and Winter Meeting donations have raised in excess of £3k.

Winter Meeting 2012

Undergraduates were offered an opportunity to apply for bursaries to present at and attend the Winter Meeting. In 2012 we received 34 applications and awarded bursaries to 29 undergraduates. The Young Pharmacologists symposium, *Pharmacology of pattern recognition receptors* was attended by ~100 delegates.

Networking events

A joint networking event was co-organized at *Biomedical Basis for Elite Performance* with the Physiological Society in March. The Young Pharmacologists also hosted the 2012 Winter Meeting Welcome Reception, which was held at SixtyOne Whitehall.

Young Life Scientists Symposium

The 2012 symposium *Future Challenges for Systems Medicine* took place on 27 June at Manchester University. The symposium attracted 61 registrants from academia, clinical and industry backgrounds.

How do drugs work?

Three short videos were recorded by the Committee at the 2012 Winter Meeting. The videos explaining Asthma, Herceptin and Painkillers can be viewed on YouTube and bps.ac.uk. Further videos will be recorded during 2013.

Voice of the Future

Organized by Society of Biology as part of National Science and Engineering Week, Voice of the Future provided a unique opportunity for young scientists to participate in a Science Question Time with Members of Parliament. Eight Young Pharmacologists represented BPS.



Members of the Young Pharmacologists Committee joined Professor Jane Mitchell and Professor Humphrey Rang at the Winter Meeting Welcome Reception

External affairs

2012 was a year of partnership for BPS External Affairs, which delivered success across collaborations, science policy and media. Ultimately, 2012 confirmed that our strategic partnerships ensure BPS is better informed and communicate the value of pharmacology to wider audiences.

National and international collaborations

BPS External Affairs prioritised engagement with UK cross-sector bodies and continued to work with valued partners such as the Physiological Society, British Neuroscience Association and Royal Pharmaceutical Society to name but a few. This was exemplified perfectly by our attendance at *Society for Neuroscience 2012* in New Orleans: primarily supporting a stand in the exhibition hall and a *BJP*-sponsored symposium on 'Revolutions in GPCR Signalling: Structure and Signals' to promote the Society and our publications, but BPS officers were also able to meet with counterparts at the British Neuroscience Association.

In addition, the External Affairs Committee was responsible for strengthening BPS interactions with other pharmacology societies in 2012.

Through joint symposia and meetings, educational and outreach events, and science policy initiatives, BPS collaborated with International, European, American, Australian, Chinese, and Austrian pharmacological societies. We also met with the leaders of six separate European pharmacological societies at the 2012 EPHAR Congress.

A new award scheme was established by the BPS External Affairs Committee and ASCEPT to support post-PhD early career researchers in both Societies. The BPS/ASCEPT Outstanding Young Investigator Award will present a significant career-enhancing opportunity for this group and promote excellence in the discipline of pharmacology by giving the best candidates the opportunity to shine on an international stage. ASCEPT selected their first participant during in December 2012, who will visit the UK for up to three weeks during 2013. BPS looks forward to selecting our participant at *Pharmacology 2013*, who will visit Australasia during 2014.

The Society intends to maintain its international profile, an objective that was boosted by expressions of interest from three BPS candidates for roles on the Executive

Committee of IUPHAR from 2014, all of which were supported by Council and are due to be considered by the IUPHAR membership in the coming year.

Science policy

BPS has been fully engaged in the UK policy arena to ensure that the importance of pharmacology and the views of pharmacologists are fully represented in government.

Funders' Group

BPS is one of seven learned societies working collaboratively with Society of Biology to fund the work of Dr Stephen Benn in support of the entire breadth of UK Science.

Due to our participation in this Funders' Group, BPS was actively involved in the Science Parliamentary Links Day on 26 June 2012, when societies and MPs including the Rt Hon David Willetts MP gathered in the House of Commons to celebrate 'science and sport' and thereby provide MPs with a more rounded understanding of current issues in science. A group of BPS members led by BPS President Professor Phil Routledge

External affairs (continued)

and Vice President–External Affairs Professor Chris Garland met with Rt Hon Roger Williams, Liberal Democrat MP for Brecon and Radnorshire, and a member of the Science and Technology Select Committee, to raise BPS policy issues such as the need to protect the skills base and the value of pre-competitive data to the drug discovery and development industry.

In December 2012, a seasonal reception for science and engineering was held to provide an informal setting for networking between the scientific community and Parliamentarians. Invitations included the BPS logo as one of the Funders' Group organizations, Jonathan Brüün (see image) marked the event with a presentation focusing on the work of pharmacologists and of the Funder's Group, and BPS members met with MPs, distinguished guests and counterparts at sister Societies. A BPS banner on 'How do drugs work?' was also on display next to the main stage.

Informing policy development

BPS responses to 13 key policy consultations were submitted during 2012 in order to



BPS Chief Executive Jonathan Brüün's keynote at December's Parliamentary Reception

represent the views and expertise of our members on topics including the NHS Constitution and open access publishing. In addition, BPS contributed towards a Society of Biology response on the nature of policy development in the UK, following the announcement of a new approach to consultations by the Minister for Government Policy, Oliver Letwin MP, including a range of consultation periods (i.e. no longer 12 weeks by default). Our response was sent to

the Secondary Legislation Scrutiny Committee of the House of Lords and a final report was scheduled to be released in 2013.

In addition, the Clinical Section responded to the following consultations in 2012:

- Higher Specialist Training - RCP
- Transposition of the Pharmacovigilance Directive - MHRA
- Safer Handover Consultation - RCP
- Regulation of Healthcare Professionals - Law Commission
- Concept paper on the need for revision of the note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function - EMA
- Concept paper on the need of the guideline on clinical investigation of medicinal products for the treatment of gout - EMA
- New standards for prescribing to apply to both supplementary and independent prescribing - Health & Care Professionals Council

- The development & updating of local formularies: draft guidance consultation - NICE
- Guideline for Diagnostic Flexible Bronchoscopy in Adults - British Thoracic Society

Ethical Standards in the Health & Life Sciences Group (ESHLSG)

The ESHLSG is intended as a platform for increased transparency and accountability in collaborations between the pharmaceutical industry and health professionals, for the benefit of patients. During 2012, BPS was one of 20 organisations on the ESHLSG, as our participation is vital in order that the interests of our members and UK pharmacology as a whole be represented.

BPS will continue to represent the views of our members on these concerns and, ultimately, contribute to the Society's strategic objectives around collaboration and promoting safe and effective prescribing.

Media

Quick off the mark

The 24-hour news cycle requires a faster

pace of reporting but also a faster pace of response by Learned Societies. To capitalise on opportunities for media coverage, the BPS communications team monitored international media, Twitter and other social media throughout 2012 for stories relevant to pharmacology. In total, over 30 press releases or responses were issued on behalf of the Society and our journals, including comments from eight different BPS representatives, which were reported by over 150 media outlets worldwide.

The awarding of the Nobel Prize in Chemistry to Robert J. Lefkowitz and Brian K. Kobilka for their work on GPCRs illustrates the impact that a timely response can achieve. A comment from President-Elect Professor Humphrey Rang was publically released within five hours, ensuring BPS views could be included in the Press Association report later that same day.

Establishing partnerships to maximise impact of BPS activity

Coordinated efforts with partner organizations contributed to effective public relations campaigns around core BPS activities. Collaborations flourished throughout the year

and included partnerships with the ESHLSG as well as disease-specialist organizations such as Cancer Research UK.

One of our closest working relationships is with BPS publishers Wiley-Blackwell. Our joint activity was particularly successful in raising the profile of our journals.

This is exemplified by a *BJP* review, *EPO Doping in Elite Cycling: No Evidence of Benefit, But High Risk of Harm*, for which a press release was co-written in language that would be understood by non-science journalists. As a result and due to coinciding with high-profile claims about Lance Armstrong, the review received widespread international media interest, including Bloomberg, the Sydney Morning Herald and the UK's Mail on Sunday. Wiley-Blackwell reported a noticeable impact of this media interest on the readership of this article.

Similarly, public relations for the inaugural BPS Drug Discovery of the Year award was notable for the cooperation of the winning team: BPS's announcement revealing the winning team behind vismodegib was

External affairs (continued)

covered by 16 news websites, with the support of a Roche press release and Roche Twitter activity directing followers to BPS and our Winter Meeting hashtag.



Search: [British Pharmacological Society](#)



[youtube.com/britpharmsoc](https://www.youtube.com/britpharmsoc)



[bps.ac.uk](https://www.bps.ac.uk)



[facebook.com/britpharmsoc](https://www.facebook.com/britpharmsoc)



twitter.com/britpharmsoc
twitter.com/pharmacologynow

Online communities

Our online networking communities flourished during 2012 – growing in size each and every month – reaching over 3,000 followers across all communities by the end of the year. 2012 saw further development of [@britpharmsoc](#), [facebook.com/britpharmsoc](#) and [youtube.com/BritPharmSoc](#) pages, as well as the launch of [@pharmacologynow](#).

[bps.ac.uk](https://www.bps.ac.uk) continued to be a key resource for careers information and educational resources in 2012: these pages appeared in the top 20 of those accessed by visitors, and the site as a whole finished the year with more than 55k unique hits. A new site, [PharmacologyNow.org](#) has been identified as the most appropriate channel for promoting careers in and public understanding of pharmacology in the future. This new website will form the hub of BPS educational and outreach activities, launching in 2013.

Publications

Our journals saw small decreases in their 2011 impact factors. Although disappointing, the changes were slight and we expect them to be reversed next year. The 2012 highlights from both of our journals are detailed below:

BJP

- Received 1,310 articles
- Published 590 articles
- Published 113 review articles
- 2011 Impact Factor of 4.409
- Published six themed issues/sections
- 27 Editors joined the board
- 17 Editors retired

BJP published the following themed issue/sections:

1. Fat and Vascular Responsiveness, Volume 165 Issue 3 (February 2012)
2. Molecular Pharmacology of GPCRs, Volume 165 Issue 6 (March 2012)
3. Cannabinoids in Biology and Medicine, Part II, Volume 165 Issue 8 (April 2012)
4. Secretin Family (Class B) G Protein-Coupled Receptors - from Molecular to Clinical Perspectives, Volume 166 Issue 1 (May 2012)

5. Novel cAMP Signalling Paradigms, Volume 166 Issue 2 (May 2012)
6. Cannabinoids 2012, Volume 167 Issue 8 (December 2012)

BJCP

- Received 745 articles
- Published 269 articles
- Published 45 review articles
- 2011 Impact Factor of 2.958
- Continued the occasional series on the mechanisms of truly novel recently licensed drugs
- Continued to publish a monthly 'editors' view'
- Eight International Editors and Six Executive Editors joined the board
- Two Executive Editors and three International Editors retired

BJCP published the following themed issue/sections:

1. Agenda for Clinical Pharmacology, Volume 73 Issue 6 (June 2012)
2. Prescribing, Volume 74 Issue 4 (October 2012)

BJCP published the following Abstracts:

- Proceedings of the British Pharmacological Society Clinical Pharmacology Section, 13–15 December 2011, Queen Elizabeth II Conference Centre, London Volume 73, Issue 6, pp. 983–1013 (June 2012)

Pharmacology Matters

The following three issues were published in 2012:

- Developing new medicines; what are the hurdles? (April 2012)
- European pharmacology (July 2012)
- Raising the profile of pharmacology through public engagement (December 2012)

July's issue was included in 1,200 delegate bags at EPHAR 2012. July's issue achieved 7,780 unique clicks from 38 countries (5,061 from UK). December's issue achieved 6,258 unique clicks from 31 countries (3,371 from UK). BPS member Dr Tim Atkinson replaced Jonathan Brünn as Editor-in-Chief.

Structure, Governance and Management

The Society's governing document is its Memorandum, Articles of Association, and Rules. In 1994, the Society became a Company Limited by Guarantee and therefore has no share capital. In the event of its winding up, the members' liability is limited to £1 each. At the Annual General Meeting (AGM) on 16 December 2010, the members resolved by Special Resolution to adopt modern, revised Articles of Association (incorporating the Memorandum).

The Trustees are legally responsible for the overall governance, strategy, and direction of the Society. In terms of the Charities Act 2006, Trustees are accountable to the Charity Commission for ensuring that the Society's objectives as a registered charity are being met. The Trustees are also the Directors of the British Pharmacological Society. The Council of Trustees, which meets twice a year, comprises the President (Chair), President-Elect, Honorary Treasurer, Chairman of the Committee of Heads of Pharmacology, Chairman of the Heads and Professors of Clinical Pharmacology and Therapeutics, and four elected members (of whom at least one is from industry and one from the clinical section at the time of election). A full list of the 2012 trustees can be found on P42.

Elections to the Council take place each

year at the AGM, and any eligible member of the Society, ordinarily resident in the UK, can stand. Trustees are elected to serve for periods of between three and four years, depending on office.

Trustee induction and training

A job description has been produced for Council members, which specifies the knowledge, skills, and attributes that are needed by the candidates. Trustee training is undertaken at regular intervals.

Executive Committee

Council has delegated responsibility to the Executive Committee to oversee the day to day operations of the Society. Members of the Executive Committee are the elected officers of BPS, together with two members directly elected by the membership. The usual term of office for Executive Committee members is three years.

Committees and Working Groups

The Council (and Executive Committee) also have Committees and Working Groups, to whom powers are delegated. The Committees and Groups report back to Council directly or via the Executive Committee, depending on their constitution. Members of these Committees and Groups

comprise both Council and/or Executive Committee appointments, together with other members. The Clinical Pharmacology Section Committee (which is a committee of the Executive Committee) manages the affairs of the Clinical Pharmacology Section. The Journals are managed by the Executive Management Committees of their Editorial Boards.

Management

The Council has ultimate responsibility for the Society's management, with the exception of those matters that must be decided by a general meeting of the members. The Council focuses on strategy and the Executive Committee is delegated the responsibility for the general management of the Society's activities. The Trustees employ a Chief Executive, who is responsible for executing the decisions of committees and sub-committees and for the day to day management of the Society's resources, including the other employees and the Angel Gate building. At 31 December 2012 we had 12 members of staff and utilized the services of specialist consultants as required. Staff and their respective job titles can be found on p42. The Chief Executive reports back to Council and Executive Committee on performance against the objectives of BPS.

The Society benefits from a great deal of voluntary work by its members in the organization of meetings, editing, and refereeing of manuscripts, service on committees and panels, and many other activities.

The Society participates actively in the wider biosciences community, both in the UK and internationally, through a variety of activities, including collaborative funding of research and education initiatives and the hosting of scientific meetings.

Risk assessment

The Trustees regularly review the risks to which the Society is exposed, particularly activity, operational, and financial risks, and ensure that procedures and reporting regimes to manage and reduce any identified risks are in place.

The prime risk to which the Society is exposed continues to be financial, particularly in respect of the income from our journals. This risk is the predominant determinate of the level of free reserves held by the Society pursuant to its Reserves Policy.

Donors during 2012

We are most grateful to the following

organizations for donations to support our various activities, including meetings, journals, prizes and training courses: Actelion, Abbott, ADInstruments, Echo Pharmaceuticals, Ellegaard Göttingen Minipigs A/S, Gilead, GlaxoSmithKline, GW Pharma Ltd, Heptares, MedImmune, Pfizer, STI Pharmaceuticals, The University of Oxford - Department for Continuing Education, TSE Systems, and Wiley Blackwell.

Exhibitors during 2012

Ascent Scientific
BMGRP
Buxco
Cambridge Bioscience
Cisbio Bioassays
DMT A/S
DSI UK
Elsevier
Ellegaard Göttingen Minipigs A/S
Guide to Pharmacology
Moor Instruments
Radnoti Ltd
STI Pharmaceuticals Ltd
Tocris
TSE Systems

Wiley Blackwell
World Precision Instruments

Professional advisers

Bankers: Cooperative Bank plc

Solicitors: Messrs Boyes Turner and Taylor Vinters

Auditors: French Duncan LLP (Chartered Accountants & Registered Auditors)

VAT Consultants: Haslers (Chartered Accountants)

Investment Managers: Brewin Dolphin

Council 2012



President
*Professor Phil Routledge**



President-Elect
*Professor Humphrey Rang**



Honorary Treasurer
*Dr Robin Hiley**



Co-Chair CHOPT
Professor Ian Kitchen



Co-Chair CHOPT
Professor Donald Singer



Elected Trustee (Industry)
Dr Ann Hayes

* Executive Committee



Co-opted Trustee
Professor Ann Daly



Elected Trustee
Dr Mark Christie



Elected Trustee
Professor Helen Cox



Elected Trustee (Clinical)
Professor Emma Baker



Co-opted Trustee
Dr Christine Williams



Trustee
David O Douglas

Executive Committee 2012



BJCP Editor-in-Chief
Professor James Ritter



BJP Editor-in-Chief
Professor Ian McGrath



Chair of the Clinical Section
Professor Munir Pirohamed



Co-opted Member
Professor Jane Mitchell



Elected Member
Dr Mike Curtis



Elected Member
(retired April 2012)
Dr Martin Todd



Vice President–Academic
Development
Professor Nicolas Goulding



Vice President–Clinical
Dr John Thompson



Vice President–External Affairs
Professor Christopher Garland



Vice President–Meetings
Professor David Webb

BPS staff



Chief Executive (until June 2012)
Kate Baillie



Deputy Chief Executive
Kevin Kearns



Chief Executive (from June 2012)*
Jonathan Brünn



Head of Education
Jess Strangward



Head of Meetings and Events
Karen Schlaegel



Head of Communications and Membership (from October 2012)
Katharine Richardson

* Director of Communications and Business Development until May 2012



Marketing and
Communications Manager
Hazel O'Mullan



Information Systems Manager
Carol Medall



Policy and Secretariat
Manager *Ruth Meyer*



Membership and Awards
Officer *Paul Tizard*



Events Officer
Becky Hughes



Education and Outreach
Officer *Rebecca Tibbs*



Accounts Administrator
Sue Giles

Financial review

Summary of 2012 financial results

The Society's surplus on unrestricted income and expenditure before unrealized gains (or losses) was in line with the previous year at £214.0k (2011: £229.5k). However after taking into account net expenditure on restricted fund activity of £316.3k (2011: £188k), there was a net expenditure of £102.4k (net income in 2011: £41.5k).

The Society has net assets of £5,993.6k (2011: £5,814.4k) including £3,413k (2011: £2,965k) in investments. It has to report on the impact of any revaluation made at the year end and for 2012 this revaluation resulted in the inclusion of £281.6k as unrealized gains (2011: £177.1k unrealised losses) resulting in a reported increase in funds of £179.2k (2011: a decrease of £135.5k). The total unrestricted activity produced a surplus of £495.6k (2011: £52.4k).

Income and expenditure

The Society's unrestricted income was similar to 2011, at £3,164.8k (2011: £3,103.4k), and the income from charitable activities was also similar at £2,947.3k (2011: £2,934.5k). Income from publishing activities remained the largest source of charitable income at £2,718.4 (2011: 2,654.2k) Expenditure on unrestricted charitable activities increased by £153k to £2,890.6k during 2012. Publishing costs at £1,262.7k (2011: £1,134.2k) were the largest expenditure at 44 % (2011: 41%). The remaining unrestricted expenditure on charitable activities of £1,628k (2011: £1,604k) was spent as indicated by the figures on charitable expenditure chart below. All these activities form part of the core objectives of the Society.

Figure: Charitable income (£2,947.3k)





Figure: Unrestricted charitable expenditure (£2,890.6k)



Financial review

Publications

BJP and *BJCP* continued to provide the substantive portion of the Society's unrestricted funds. Total subscriptions of 4,568 were reported for *BJCP* (2011: 4,274), including licensed subscriptions and licensed collection sites but excluding traditional year-by-year institutional subscriptions, and for *BJP* the same figure was 1,223 (2011: 1,131). Both journals maintained satisfactory renewal rates: 98% for *BJP* and 93.55% for *BJCP*.

Education and scientific meetings

Disseminating excellent scientific research by running high quality scientific meetings is one of the Society's core objectives. During 2012, BPS delivered three Focused Meetings and our annual Winter Meeting, which was fully booked in advance for the second year in a row. BPS meetings attracted more than 1,200 delegates in total, of which 54% were non-member registrations. This was associated with revenue of £94k (in 2011 the figure was £157.9k largely due to sponsorship for the ET12 Endothelin Conference) and expenditure of £575.4 (2011: £574.7k).

BPS members continued to enjoy free access to the Society's main meetings and thus revenue derives mainly from non-member registration fees, fees for Focused Meetings, trade exhibitions and sponsorship.

The Society also supported pharmacology through its Diploma in Advanced Pharmacology (from which six members graduated in 2012), funding 51 days of graduate *in vivo* training, and distributing £370.5k (2011: £118.7k) of grants through the Integrative Pharmacology Fund. Unrestricted expenditure on educational activities during the year was £412.5k (2011: £397.9k) including grants totaling £213.0k (2011: £313.5k) to institutions, and £27.3k (2011: £25.7k) of prizes to science and medical undergraduates.

Bursary grants to individuals totaled £32.3k, enabling 125 members to participate in BPS and third party meetings.

Member services

Income from membership subscriptions

continues to reflect our stable membership portfolio. Total unrestricted expenditure on services for members in the period under review was £519.9k (2011: £487.9k). BPS continued to offer financial support to other organisations in the sector through a range of corporate subscriptions and annual donations.

Other expenditure

Central office overheads not directly attributable to other activities were in line with expectations and there were no extraordinary expenditure items. Governance costs showed an increase over 2011 partly due to the increased cost of meetings, the cost of a Strategy Retreat that produced a five-year strategy for the Society, and 2011 costs being lower than had been expected.

Investment performance

During the year to 31 December 2012 there were considerable swings in the stock market indices mostly as a result of the financial uncertainty of countries within the European Market. However investment income was £39k higher than 2011 at

Financial review

£172k and this, added to realized gains of £14.9k, provided a further £187k in funds to the charity (compared with only £38k in 2011 when there were also investment losses of £94k and investment income of £132k).

The charity is required to report on the change in value of its investment portfolio at each year end as unrealized gains or losses. In 2012 this revaluation created an unrealized gain of £281.5k compared to a decrease in 2011 of £177k, though the investment fund rose by net additions of £166k, resulting in an overall increase in investments to £3,413k (2011: £2,965k).

In 2012 we continued our investment strategy and worked with our Investment Manager to ensure our Liquidity Fund met the requirements of our Reserves Policy. Since 1 June 2010 our investments have been split into a Liquidity Fund and a separate Growth Fund. Since the split, the Growth and Liquidity Funds portfolios are being measured against the APCIMS (Association of Private Client Investment Managers and Stockbrokers) Balanced and the FTSE Government All Stocks

benchmarks respectively. In the period since the portfolios were restructured, these rose by 21.0% and 20.1% respectively, whilst the FTSE 100 Index of Leading Shares rose by 24.9%.

Restricted funds

Our restricted fund balances remain wholly adequate to support current levels of commitments and liabilities. The largest portion of restricted funds is the Integrative Pharmacology Fund, which promotes research and training in integrative pharmacology. Major donations during the period (£187k) resulted from industry support for the Society's *in vivo* educational activities and government support for the development of e-learning initiatives for medical students.

Balance sheet

After accounting for the movements detailed above, the balance sheet continues to show that the Society has the financial resources required to meet its charitable objects.

Reserves policy

The Trustees have examined the Society's methods of calculating a reserve level that represents a figure that would allow its commitments to members, both in terms of operations and activities to continue over a period of at least two years if its major source of revenue failed. The reserves reported at 31 December 2012 are in excess of that level and this allows the Society to consider additional activities to further its objectives.

Investment policy

The Society's investments are managed on a fully discretionary basis by Brewin Dolphin Securities.

The current investment strategy is designed to underpin the Society's free reserves requirement, by providing a buffer against sudden loss of income from its traditional activities (pending restructuring to a revised, balanced budget). We also need to invest to meet medium/long-term liabilities which may arise from our usual activities, to hedge against future inflation and to provide for major capital expenditure.

Financial review

In the period under review, and with guidance and assistance from its Investment Manager, the Society continued to review and restructure its invested assets to provide long term growth and income (from a balanced, diversified, medium risk weighted, portfolio); and liquidity (from a portfolio including UK and foreign bonds, government securities and cash).

Public benefits test

The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2006 to have due regard to the Charity Commission's general guidance on public benefit "Charities and Public Benefit".

The Society is the primary UK learned society concerned with research into drugs and the way they work. The Society's activities support the education of scientists, clinicians, university and school students, the general public and the dissemination of research in pharmacology and clinical pharmacology. Pharmacology is responsible for the discovery and successful use of hundreds of chemicals

used in the treatment of disease and the relief of human and animal suffering, as well as contributing substantially to the success of the pharmaceutical and healthcare industries.

Honorary Treasurer's statement

There has been much change within the Society during 2012, as has been reported earlier in this Annual Review. Here, my responsibility as Honorary Treasurer is to summarise the impact of these changes upon the financial outcomes for the year. We report in accordance with Charity Commission guidelines that require us to separate our financial activities into unrestricted funds, where we have discretion on how the money is used, and restricted funds, where the money can only be used for purposes specified by the donor.

Unrestricted activities produced a net income of £214k in 2012, but this was increased by £282k (to £496k) after adding the gain created through the year-end revaluation of our investments. As the revalued investments are still held

by the Society, this is a paper gain only (last year we had a paper loss of £177k). Meanwhile, the restricted funds stood at £905k at the beginning of the year, and subsequently fell to £589k by the year-end; that reduction of £316k is reported as an expenditure in the Statement of Financial Activities.

Overall, the Charity is reporting a surplus of funds for the year of £179k compared to a net outflow in 2011 of £136k. Our reserves therefore have increased to £5,994k from £5,814k.

Publishing trends, as reflected in the journals' accounts, show a growing urgency for the Society to identify other possible sources of income as net income is essentially static. All departments are presently charged with looking for opportunities to develop their income streams in order to rebalance the Society away from its heavy dependence on the publishing income.

Nevertheless, the overall picture shows that the Society is sufficiently resourced to be able to continue to deliver its charitable

Financial review

objectives in the medium term. As noted above, the Council (comprised of the Society's Trustees) has agreed a level of reserves that should allow the Society sufficient time to develop new initiatives while allowing it to fulfil its primary objectives.

The Finance & Risk Committee (FRC) has continued to be the main support to the Trustees and Executive Committee in reviewing the Society's finances and maintaining vigilance on the risks in its activities. Arising from the Trustees' Strategic Review, a new budgeting process has been developed which will work on a rolling three-year basis. This is being strengthened by the introduction of a new form of Management Accounts which will allow the Society's staff and officers to see more clearly how their income and expenditure are moving through the year relative to their budget.

I am pleased to conclude by noting that the Society remains in a strong financial position. We are well placed to face new financial challenges as they arrive, and the Society's staff and officers are

seeking new opportunities to broaden our financial base. I look forward to working with my colleagues on the FRC, Executive and Council to develop the means for the Society to continue to make its strong contribution to the discipline through engagement and support of its members, pharmacology throughout the world, and the general public.

Summary Financial Statement

The financial information set out in this Summary Financial Statement is only a summary of information derived from the Charity's Annual Accounts. It does not contain additional information derived from the Trustees' Annual Report. It does not contain sufficient information to allow as full an understanding of the results and state of affairs of the Charity as would be provided by the full Annual Accounts and Report.

Members requiring more detailed information can obtain a full copy of the Charity's Annual Accounts and Trustees' Annual Report from the BPS Office or from the Member Information section of the

Society's website. Members who wish to elect to receive a full copy of the Annual Accounts for all future financial years should contact the BPS Office.

Statement of the Independent Auditor to the Members of the British Pharmacological Society

We have examined the Summary Financial Statement for the year ended 31 December 2012.

Respective responsibilities of the trustees and the auditor

The Trustees (who also act as Directors of the Charity for the purposes of Company Law) are responsible for preparing the Summary Financial Statement in accordance with applicable United Kingdom law.

Our responsibility is to report to you our opinion on the consistency of the Summary Financial Statement with the full Annual Financial Statements, and its compliance with the relevant requirements of section 427 of the Companies Act 2006 and the regulations made thereunder.

Financial review

We conducted our work in accordance with Bulletin 2008/3 issued by the Auditing Practices Board. Our report on the Company's full Annual Financial Statements describes the basis of our opinion on those financial statements.

Opinion

In our opinion the Summary Financial Statement is consistent with the full Annual Accounts of British Pharmacological Society for the year ended 31 December 2012 and complies with the applicable requirements of section 427 of the Companies Act 2006, and the regulations made thereunder.

FRENCH DUNCAN LLP
Chartered Accountants and Registered
Auditors

56 Palmerston Place
Edinburgh
EH12 5AY

Statement of Trustees

The Auditor has issued unqualified reports on the full Annual Accounts and on the consistency of the Trustees' Annual Report with those Annual Accounts.

Their report on the full annual accounts contained no statement under sections 498(2) or 498(3) of the Companies Act 2006.

Signed on behalf of the Trustees by:

C R Hiley, Honorary Treasurer

Financial review

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 DECEMBER 2012

INCOMING RESOURCES

	Unrestricted Funds	Restricted Funds	Total Funds Year to 31 Dec 12	Total Funds Year to 31 Dec 11
Incoming Resources from generating funds:				
Voluntary Income		346,480	346,480	167,409
Activities for generating funds	2,947,356		2,947,356	2,934,531
Investment Income	170,736	1,259	171,995	132,100
Other Incoming Resources	49,735		46,735	48,205
TOTAL INCOMING RESOURCES	3,164,827	347,739	3,512,566	3,282,245

RESOURCES EXPANDED

Cost of generating funds:				
Investment management costs	(18,614)		(18,614)	(18,139)
Charitable Activities	(2,890,567)	(689,074)	(3,579,642)	(3,109,940)
Governance Costs	(31,506)		(31,506)	(18,627)
Other Resources Expended				
TOTAL RESOURCES EXPANDED	(2,940,687)	(689,074)	(3,629,762)	(3,146,706)

Financial review

	Unrestricted Funds	Restricted Funds	Total Funds Year to 31 Dec 12	Total Funds Year to 31 Dec 11
NET INCOMING/(OUTGOING) RESOURCES BEFORE TRANSFERS	224,139	(341,335)	(117,196)	135,539
Transfer between funds	(25,000)	25,000		
NET INCOMING/(OUTGOING) RESOURCES FOR THE YEAR BEFORE INVESTMENT ASSET DISPOSALS	199,139	(316,335)	(117,196)	135,539
Realised Gains/(Losses) on disposal of investment assets	14,872		14,872	(93,997)
NET INCOMING RESOURCES/ (RESOURCES EXPENDED) (BEFORE REVALUATIONS)	214,011	(316,335)	(102,323)	41,542
Realised Gains/(Losses) on disposal of investment assets	281,571		281,571	(177,070)
NET MOVEMENT IN FUNDS FOR THE YEAR (Carried Forward)	495,582	(316,335)	179,247	(135,528)

Financial review

	Unrestricted Funds	Restricted Funds	Total Funds Year to 31 Dec 12	Total Funds Year to 31 Dec 11
<i>Brought Forward</i>	495,583	(316,335)	(179,248)	(135,528)
RECONCILIATION OF FUNDS				
Total funds at 1 Jan 2012	490,936	905,047	5,814,409	5,949,937
TOTAL FUNDS CARRIED FORWARD	<u>5,404,944</u>	<u>588,712</u>	<u>5,993,657</u>	<u>5,814,409</u>

The Statement of Financial Activities includes all gains and losses in the year and therefore a statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

BALANCE SHEET 31 DECEMBER 2013

	2012	
	£	£
FIXED ASSETS		
Tangible Assets	623,431	641,607
Investments	<u>3,412,993</u>	<u>2,965,052</u>
	<u>4,036,424</u>	<u>3,606,659</u>

Financial review

BALANCE SHEET 31 DECEMBER 2013 (Continued)

	2012		
	£	£	£
CURRENT ASSETS			
Debtors		697,039	685,935
Investments		-	1,035,740
Cash at Bank and in hand		2,367,200	1,349,150
		<u>3,064,239</u>	<u>3,070,825</u>
CREDITORS: amounts falling due within one year			
	<u>(1,034,168)</u>		<u>(777,498)</u>
NET CURRENT ASSETS		<u>2,030,071</u>	<u>2,293,327</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		6,066,495	5,899,986
CREDITORS: amounts falling due after more than one year		<u>(72,838)</u>	<u>855,771</u>
NET ASSETS		<u>5,993,657</u>	<u>5,814,409</u>
CHARITY FUNDS			
Unrestricted Funds		5,404,945	4,909,362
Restricted Funds		558,712	905,047
		<u>5,993,657</u>	<u>5,814,409</u>

These financial statements were approved and signed on behalf of the Trustees on 31 May 2013 by: **C R Hiley** Honorary Treasurer
Company Registration Number: 2877400

BPS objectives 2013

1. Development of an integrated publications strategy, including:

- Ensuring the Society's new Publications Committee delivers a coherent, strategic vision for our journals; to include coordination of a Journals Strategy Retreat and the development of a plan to improve and maintain quality of publication given online opportunities
- Continued engagement with open access publishing, through the launch of a new journal in tandem with the (ASPET and Wiley-Blackwell, and GuidetoPharmacology.org with the IUPHAR
- Greater integration of the Society's journals with its other activities, including membership initiatives, committee activities, meetings organisation and abstract publishing processes, outreach and promotional work

2. Greater matching of the Society's activities to the needs of the Membership, by:

- Conducting a member engagement campaign with a view to ensuring that targeted services and rewards are provided for specific member cohorts, increasing BPS membership, particularly at Full Member level, and promoting 'career membership' of the Society
- Ensuring that a sufficient number of volunteers are recruited to the roles essential for the running of the Society, in support of a comprehensive succession plan for the Society's activities
- Commissioning a new, integrated BPS member database to provide a better service for our members and committees
- Continued provision of high quality scientific meetings targeted to areas of need and interest

3. Explaining the importance of pharmacology in the modern world by extending BPS education and outreach activities, including:

- Providing high quality educational courses and workshops, to be enhanced by integrated elearning and Continuing Professional Development programmes
- Developing a portfolio of online careers information for A-Level students and undergraduates
- Supporting the provision of high quality in vivo training, in particular through continued engagement with Society of Biology's accreditation project
- Ensuring that pharmacology is fully represented in government and among policy makers

BPS objectives 2013

4. To reflect the increasingly multi-disciplinary nature of modern biomedical science by further developing BPS's collaborative activities with other Societies, including:

- Contributing to government's Life Sciences Strategy initiative, with sector partners, and through the collaborative work of the Drug Discovery Pathway Group
- Recommending approaches to support and sustain the UK skills base, in tandem with a broad cohort of Learned Societies
- Continued engagement with partners on policy initiatives to highlight the importance of pharmacology and clinical pharmacology in the health and wealth of the UK

5. BPS should maintain its central position in the promotion of clinical pharmacology, the promotion of safe and effective prescribing, and in the discovery and development of medicines in the UK, by:

- Delivering outcomes from the 5-Year Agenda for Clinical Pharmacology meeting, including the development of careers resources, web resources, and a stronger public image
- Further developing the quality and scope of the Society's CPT educational resources, including Prescribe, the Prescribing Simulator and the PSA through the delivery of a national pilot for final year medical students
- Exploring a long term role for the PSA, in tandem with key partners
- Fostering excellence in research in clinical pharmacology to emphasise that it remains a key discipline in translating basic and applied research findings into clinical practice



**BRITISH
PHARMACOLOGICAL
SOCIETY**

Today's science, tomorrow's medicines